History
2025
FDA CMC Meeting
03
2024
Publication in Neuroscience Reports
11
US Patent Approved for AL04 (USPTO)
10
Added Poster Presentation at the AAIC in Philadelphia
(Alzheimer’s Association International Conference) 07
(Alzheimer’s Association International Conference) 07
Presentation of BIO International Convention in San Diego
06
Presentation of JPM Biotech Showcase
in San Francisco 01
in San Francisco 01
2022
Publication in Neuroscience Letters
10
Pre-IND Submission (US FDA)
08
2021
Signing of CRO Contract for Preclinical Studies
and Progression of Preclinical Trials 12
and Progression of Preclinical Trials 12
2020
$4,300,000 Fund Raised
03
Holding an IR Presentation
01
2019
Industry partner in a national project for
developing membrane modules
and culture systems for cell cultivation. 11
developing membrane modules
and culture systems for cell cultivation. 11
Patent Application for 'Method for
Treating Central nervous system disease(AL04)' 08
Treating Central nervous system disease(AL04)' 08
Venture Company Certification
05
2018
Certification of In-House Research Institute
06
2017
Acquire a Patent ‘Method for Treating Shingles with
N-Methanocarbathymidine (N-MCT) 09
N-Methanocarbathymidine (N-MCT) 09
2016
Establishment of L&J Bio, Co., Ltd. (KR)
12
2012
Establishment of L&J Bio
10
